Market Research Report
Global Pulmonary Drug Delivery Systems Market by Product - Global Scenario, Market Size, Outlook, Trend and Forecast, 2016-2025
|Published by||Variant Market Research LLP||Product code||649275|
|Published||Content info||101 Pages
Delivery time: 1-2 business days
|Global Pulmonary Drug Delivery Systems Market by Product - Global Scenario, Market Size, Outlook, Trend and Forecast, 2016-2025|
|Published: June 3, 2018||Content info: 101 Pages||
Global pulmonary drug delivery system market is estimated to reach $54.9 Billion by 2025 with CAGR of 6.2% between 2017 and 2025. Pulmonary drug delivery system is used to target diseases in the airways by delivering locally acting drugs directly to their site of action. Pulmonary route of drug delivery offer advantages such as small amount of drug, less adverse reaction and rapid onset of action. Increasing prevalence of chronic respiratory diseases like asthma, bronchitis is expected to grow the market of Pulmonary Drug Delivery Systems.
The major factors that fuel the market are; rising air pollution, increase in smoking, tuberculosis, chronic obstructive pulmonary disease, increasing demand for non-invasive methods, technological advancements such as smart inhaler, increasing geriatrics population. However, regulatory approvals and patent expiration of drugs may hamper the growth of global pulmonary drug delivery market. Moreover, rise in use of online marketing creates further opportunities for the market to sustain in the upcoming years.
The global pulmonary drug delivery systems market is segmented on the basis of product, application, and geography. On the basis of product, it is divided into metered dose inhalers (breath-actuated pressurized inhaler and manually-actuated pressurized inhaler), nebulizers (jet nebulizers, ultrasonic nebulizers, and vibrating mesh nebulizers), and dry powder inhalers (single dose inhalers and multi-dose inhalers). On the basis of distributor segment it is bifurcated into retail pharmacies, hospital pharmacies, and e-commerce. On the basis of application, the market is segmented into asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD), and others.
By geography, the global pulmonary drug delivery system market is segmented into North America, Europe, Asia-Pacific, and Rest of the world (RoW). The U.S., Canada, and Mexico are covered under North America wherein Europe covers UK, Germany, France, Italy, and others. Asia-Pacific covers China, India, Japan, South Korea, and others. Rest of the World covers South America, Middle East and Africa.
Key players in pulmonary drug delivery system market include: AstraZeneca plc, Boehringer Ingelheim Gmbh, GlaxoSmithKline plc, Novartis AG, Koninklijke Philips N.V., 3M Company, Actelion Pharmaceuticals Ltd, Clement Clarke International, Briggs Healthcare, and Aerogen.
Distribution Channel Segments